Skip to main content
    T

    Taysha Gene Therapies Inc (TSHA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.00
    -0.06 (-1.48%)

    Market Cap: $1.32B

    Last updated: Nov 17, 2026 at 4:11 PM ET

    Taysha Gene Therapies Inc (TSHA) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Taysha Gene Therapies (TSHA) has a market cap of $1.32B and an enterprise value of $948.24M. It kept -2844.63% of revenue as net income over the last 12 months. Its share count is up 14.94% from a year earlier.

    Total Valuation

    Enterprise value is 28.37% below the market cap, as cash exceeds debt.

    Market Cap$1.32B
    Enterprise Value$948.24M
    Latest price (Nov 17, 2026)$4.00

    Key Dates

    The next earnings report is expected on Mar 17, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 17, 2027 (expected)
    Last Earnings DateNov 12, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 10.04% in the quarter ended Sep 30, 2026 and grew 23.14% a year over 2 years.

    Shares Outstanding406.11M
    Shares Change (YoY)+14.94%
    Shares Change (QoQ)+10.04%
    Share Count Growth (2Y CAGR)+23.14%

    Valuation Ratios

    Sales and book value multiples are 296.2x and 4.6x. Its year-end P/S ranged from 10.5x to 169.9x from 2022 to 2025.

    P/S Ratio296.2x
    P/B Ratio4.6x

    Valuation history and multiples

    Price Statistics

    The stock is down 3.15% over 52 weeks and trades 9.71% below its 50-day average.

    Beta (1Y)1.69
    52-Week Change-3.15%
    1-Month Change+1.52%
    3-Month Change-37.79%
    6-Month Change-22.85%
    5-Year Change-73.59%
    Total Return (1Y)-3.15%
    Total Return (3Y CAGR)+33.00%
    Total Return (5Y CAGR)-21.95%
    Return vs SPY (1Y)-15.17%
    Max Drawdown (1Y)-49.71%
    Max Drawdown (3Y)-72.90%
    Sharpe Ratio (1Y)-0.05
    Correlation with SPY (1Y)0.33
    50-Day Average$4.43
    200-Day Average$5.29
    52-Week Range$3.46 to $7.30
    RSI (14 Days)41.9
    Average Volume (20 Days)2.89M

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 18.56x current liabilities, and total debt is 0.13x shareholder equity.

    Current Ratio18.56x
    Quick Ratio18.56x
    Debt / Equity0.13x
    Interest Coverage-5409.06x

    Returns and Efficiency

    Return on invested capital is -32.76% over the last 12 months, against a 5-year average of -31.42%.

    Return on Equity (ROE)-43.71%
    Return on Assets (ROA)-35.87%
    Return on Invested Capital (ROIC)-32.76%
    ROA (5Y Average)-73.01%
    ROIC (5Y Average)-31.42%
    Asset Turnover0.01x

    Scores

    TSHA has an Altman Z-Score of 9.64, in the safe zone above 2.99, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.

    Altman Z-Score9.64
    Altman Z ZoneSafe
    Piotroski F-Score4 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $5.49M over the last 12 months is down 13.07% from the 12 months before.

    Revenue$5.49M
    Revenue Growth (YoY)-13.07%
    Gross Profit$5.49M
    Operating Income-$161.01M
    Pretax Income-$156.03M
    Net Income-$156.03M
    Reported EPS (TTM)-$0.41

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 82.06% of the $435.03M in total assets.

    Cash and Equivalents$422.83M
    Total Debt$47.33M
    Net Cash$375.50M
    Net Cash Per Share$0.92
    Working Capital$403.11M
    Shareholder Equity$356.97M
    Book Value Per Share$0.88
    Total Assets$435.03M
    Total Liabilities$78.06M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $718.00K of capital spending, operating cash flow left -$141.66M of free cash flow.

    Operating Cash Flow-$140.94M
    Capital Expenditures$718.00K
    Free Cash Flow-$141.66M
    FCF Per Share-$0.43
    Depreciation and Amortization$1.14M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -2935.41%.

    Gross Margin100.00%
    Operating Margin-2935.41%
    Pretax Margin-2844.63%
    Net Margin-2844.63%
    FCF Margin-2582.63%

    Growth

    Revenue grew 57.49% a year over 3 years.

    Revenue Growth (3Y CAGR)+57.49%
    Book Value Per Share Growth (2Y CAGR)+38.82%
    Tangible Book Per Share Growth (2Y CAGR)+38.82%

    Revenue and profit by year

    Dividends and Yields

    TSHA does not pay a dividend. Its free cash flow yield is -8.72%.

    FCF Yield-8.72%
    Buyback Yield-16.30%
    Shareholder Yield-16.30%

    Peer Position

    Against 8 similar companies, TSHA has the 2nd highest P/S.

    P/S Ratio296.2x vs 12.3x median
    ROIC-32.76% vs -38.09% median
    Revenue Growth (Trailing 4 Quarters, YoY)-13.07% vs +35.11% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 9.07% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+9.07%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About TSHA

    What is TSHA's market cap?

    Taysha Gene Therapies has a market cap of $1.32B. Its enterprise value, which adds debt and subtracts cash, is $948.24M.

    How many shares of TSHA are outstanding?

    Taysha Gene Therapies has 406.11M shares outstanding. The count is up 14.94% from a year earlier.

    Does TSHA pay a dividend?

    No. Taysha Gene Therapies does not pay a dividend.

    How much debt does TSHA have?

    Taysha Gene Therapies has $47.33M of total debt and $422.83M of cash and equivalents, a net cash position of $375.50M.